Myriam Chalabi: An important international study on whether high TILs can be used to safely omit chemotherapy in TNBC
Myriam Chalabi shared a post by The Netherlands Cancer Institute, on X, adding:
”Congratulation Marleen Kok Lab for this fantastic achievement! Great strength for an important international study on whether high TILs can be used to safely omit chemotherapy in patients with stage 1 TNBC.”
Quoting The Netherlands Cancer Institute’s post:
”Thanks to all donors to KWF Dutch Cancer Society NKI researcher Marleen Kok Lab received 4.1 million euros for large-scale international research into forgoing chemotherapy in women with early-stage triple-negative breast cancer.”
Read further.
Source: Myriam Chalabi/X and The Netherlands Cancer Institute/X
Myriam Chalabi is a Gastrointestinal Oncologist and clinician scientist at the Netherlands Cancer Institute in Amsterdam. In 2022 she was named one of the 11 early career researchers to watch by Nature Medicine. In 2023 she was awarded the ESMO José Baselga Fellowship for Clinician Scientists.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023